ACADIA PHARMACEUTICALS INC. Equity Securities, FV-NI, Cost
ACADIA PHARMACEUTICALS INC. (ACAD) had Equity Securities, FV-NI, Cost of $373.48 million as of 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Investments
us-gaap:EquitySecuritiesFvNiCost · last filed 2022-03-01
- 2021-12-31: Equity Securities, FV-NI, Cost $373.48M.
- 2021-09-30: Equity Securities, FV-NI, Cost $445.66M.
- 2021-06-30: Equity Securities, FV-NI, Cost $289.93M.
- 2021-03-31: Equity Securities, FV-NI, Cost $273.26M.
| Period end | Equity Securities, FV-NI, Cost |
|---|---|
| 2021-12-31 | $373.48M 10-K · filed 2022-03-01 |
| 2021-09-30 | $445.66M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $289.93M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $273.26M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $305.90M 10-K · filed 2021-02-25 |
| 2020-09-30 | $191.59M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $346.64M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $476.85M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $3.15M 10-K · filed 2019-02-27 |
| 2018-09-30 | $3.15M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $3.15M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |